The purpose of the Hematology/Oncology Pharmacy Association (HOPA) Continuing Pharmacy Education (CPE) Program is to provide members with opportunities for lifelong learning and assistance in fulfilling their maintenance of certification and licensure requirements, thereby promoting excellence in the provision of pharmacy care.
Definition of Continuing Pharmacy Education
Continuing education for the profession of pharmacy is a structured educational activity designed or intended to support the continuing development of pharmacists and/or pharmacy technicians to maintain and enhance their competence. Continuing pharmacy education (CPE) should promote problem-solving and critical thinking and be applicable to the practice of pharmacy.
Definition of Commercial Bias
A personal judgment in favor of a specific proprietary business interest or commercial interest.
Learner Bill of Rights
HOPA recognizes that you are a lifelong learner who has chosen to engage in CPE to identify or fill a gap in knowledge or skill and to attain or enhance a desired competency. As part of HOPA’s duty to you as a learner, you have the right to expect that your CPE experience with HOPA will include the following:
- promotes improvements or quality in health care
- is current, valid, reliable, accurate, and evidence based
- addresses the stated objectives or purpose
- is driven by and based on independent survey and analysis of learner needs, not commercial interests
- has been reviewed for bias and scientific rigor
- offers balanced presentations that are free of commercial bias
- is vetted through a process that resolves any conflicts of interest of planners and faculty
- is evaluated for its effectiveness in meeting the identified educational need.
A learning environment that
- is based on adult learning principles that support the use of various modalities
- supports learners’ abilities to meet their individual needs
- respects and attends to any special needs of the learners
- respects the diversity of groups of learners
- is free of promotional, commercial, and/or sales activities.
- relevant financial relationships that planners, teachers, and authors have with commercial interests related to the content of the activity
- commercial support (funding or in-kind resources) of this activity.
Independence in CPE
The mission of the HOPA CPE program is to improve patient care and healthcare outcomes by maintaining, developing, and enhancing medical knowledge, patient care, interpersonal and communication skills, and professionalism. As a provider accredited by the Accreditation Council for Pharmacy Education (ACPE) and in support of this mission, HOPA is dedicated to providing CPE that is independent, fair, balanced, objective, and free of commercial bias.
HOPA employs several strategies to ensure these standards will be met. HOPA’s Planning Committees’ members submit and consider their own disclosure information and recuse themselves from planning educational activities should they have conflicts related to the subject area presented. When developing an educational program, the planning committee reviews applications and disclosure of interest forms along with needs assessment and evaluative data from past activities to develop programming. Potential participants are sent detailed guidelines that provide direction on necessary components to ensure independence in CPE activities and to resolve conflict, as itemized below.
Statement of Need/Course Overview
Oncology pharmacists have a valuable place in the care of cancer patients. They have been shown to improve patient care while assisting other disciplines in the performance of their duties. The oncology pharmacist is often one of the few team members that fully understands the safety, efficacy, pharmacologic, and financial components of patient care in individuals with cancer. The changing landscape of health care and evolving approach to cancer care (e.g., oral therapies, targeted therapies, personalized medicine) emphasize the need for the oncology health care team to include an oncology pharmacist.
The Annual Hematology/Oncology Pharmacy Association Practice Management Conference is the only conference dedicated to the management and leadership for practice changes within Oncology. No other conference provides robust training to provide the skill sets necessary to manage this complex patient population. Topics for HOPA’s 5th Annual Practice Management Program, as well as scheduling, venue, and speakers, were chosen based on therapeutic advances in hematology/oncology, current medical news, input from HOPA’s planning committees, and suggestions from last year’s participants.
Upon completion of this activity, participants will be able to
- describe ways to motivate your pharmacists to maximize opportunities to provide patient care
- discuss oncology pharmacy best practices and guidelines
- develop ways to improve patient outcomes through specialty pharmacy programs
- review approaches that prove the value of oncology pharmacy practice
- outline processes to maximize reimbursement from third-party payers.
Disclosure of Conflicts of Interest
HOPA assesses conflicts of interest with its faculty, planners, managers, and other individuals who are in a position to control the content of CPE activities. All potential conflicts of interest identified are thoroughly reviewed for fair balance, scientific objectivity of studies used in the activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CPE activities and related materials that promote improvements or quality in health care and not specific proprietary commercial interests.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. HOPA and its faculty, planners, managers, and commercial supporters do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activities are those of the faculty and do not necessarily represent the views of HOPA or any other organizational or commercial entities.
Resolution of Conflict of Interest
In accordance with the ACPE Standards for Commercial Support of CPE, the Hematology/Oncology Pharmacy Association has implemented mechanisms, prior to the planning and implementation of this CPE activity, to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CPE activity.
Hematology/Oncology Pharmacy Association Accreditation Statement
The Hematology/Oncology Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
The Hematology/Oncology Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program will provide a statement for up to 8 contact hours of credit and will be available at the completion of the activity. Successful completion includes participating in the activity and completing self-assessment and program evaluation form online. A statement of participation will be available online immediately following successful completion of the activity.
How to Obtain Your ACPE Credit
Credit is determined for each module by successfully completing pre and post-assessments and an evaluation. To claim credit and to help us assess your future educational needs, you must complete the evaluation process by November 9, 2017. After November 9, 2017, you will not be able to submit an evaluation for credit. After you have completed your evaluations, HOPA will report your credits to CPE Monitor for transmittance to NABP.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.